

How Blue Cross and BCN are handling authorizations for Makena® following FDA announcement

In a [news release](#) dated April 6, 2023, the U.S. Food & Drug Administration announced it has withdrawn its approval of Makena (hydroxyprogesterone caproate), HCPCS codes J1726 and J1729. This decision also applies to generic Makena products.

This means that Makena and its generic products are now unapproved and cannot lawfully be distributed in interstate commerce.

For Blue Cross Blue Shield of Michigan and Blue Care Network commercial members, here's how we're handling authorizations for Makena:

- We'll honor prior authorization requests that have already been approved for this medical benefit drug through their end dates.
- Due to the change in approval status from the FDA, we're denying prior authorization requests submitted for dates of service on or after April 6, 2023.

These changes apply to:

- All Blue Cross and BCN commercial members
- All versions of Makena, including compounded and generic versions

We've updated the pertinent drug lists to reflect this change.